Most patients experience no pain, no systemic effects, and no disruption to their treatment
In contrast, co-treatment of semaglutide with the amylin receptor agonist cagrilintide resulted in 29% of patients with obesity and T2D reporting nausea compared to 13% for cagrilintide alone and 16% for semaglutide alone ( Figure 1 Figure 2 3 Mechanisms of action for GLP-1R agonists to control food intake GLP-1R agonists primarily act to reduce body weight by suppressing energy intake
Biomarkers for distinguishing association with major cannabinoids in children with ASD based on response to MC treatment Cannabis-responsive biomarkers specifically categorized by THC, CBD and CBG can indicate the metabolic pathways that are affected by cannabinoids in children with ASD (Fig
Patients hold overwhelming demand for GLP-1s, but access (supply + list price cost) creates constraints Employers and payors are grappling with benefit design and coverage access qualifications for GLP-1s (e.g., limiting to diabetes patients)
It reduces -amyloid deposition, inhibits glutamate production, prevents ferroptosis, and restores synaptic plasticity
doi: 10.1056/NEJMoa1911303 144
